JP2011518153A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518153A5 JP2011518153A5 JP2011504974A JP2011504974A JP2011518153A5 JP 2011518153 A5 JP2011518153 A5 JP 2011518153A5 JP 2011504974 A JP2011504974 A JP 2011504974A JP 2011504974 A JP2011504974 A JP 2011504974A JP 2011518153 A5 JP2011518153 A5 JP 2011518153A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- week
- gemcitabine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 4
- 229960005277 gemcitabine Drugs 0.000 claims 4
- 230000000394 mitotic Effects 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- 229960004117 Capecitabine Drugs 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N Clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims 1
- 229960000684 Cytarabine Drugs 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 1
- 229960000961 Floxuridine Drugs 0.000 claims 1
- 229960002949 Fluorouracil Drugs 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010025310 Other lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 101700005340 PLK Proteins 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 229960002340 Pentostatin Drugs 0.000 claims 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- LBGFKUUHOPIEMA-PEARBKPGSA-N Sapacitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](C#N)[C@H](O)[C@@H](CO)O1 LBGFKUUHOPIEMA-PEARBKPGSA-N 0.000 claims 1
- 229950006896 Sapacitabine Drugs 0.000 claims 1
- 229960005454 Thioguanine Drugs 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 229960002436 cladribine Drugs 0.000 claims 1
- 229960000928 clofarabine Drugs 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 229960003603 decitabine Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Claims (9)
- 有糸分裂攪乱物質/ポロ様キナーゼ(Plk)経路阻害剤を含有する、ヌクレオチド類縁化学療法剤による治療に感受性がある癌を治療するための医薬組成物。
- 癌が、ヌクレオチド類縁化学療法剤に耐性の腫瘍、ゲムシタビン耐性癌、白血病、リンパ腫、結腸直腸癌、膵臓癌、肺癌、乳癌、卵巣癌、基底細胞癌、膀胱癌、肝臓癌、前立腺癌、胃癌、腎臓癌、メラノーマ、神経膠腫、食道癌、子宮頸癌、及び骨髄異形成症候群よりなる群から選ばれる、請求項1に記載の医薬組成物。
- ヌクレオチド類縁化学療法剤及び有糸分裂攪乱物質/Plk経路阻害剤を含有してなる、医薬組成物。
- 有糸分裂攪乱物質/Plk経路阻害剤が、Plk1阻害剤を含有してなる、請求項1〜3の何れか一項に記載の医薬組成物。
- 有糸分裂攪乱物質/Plk経路阻害剤が、ON01910又はそれらの誘導体を含有してなる、請求項1〜4の何れか一項に記載の医薬組成物。
- 医薬組成物が、ON01910−Na又はそれらの誘導体を50mg/m2/week〜5000mg/m2/weekの用量で投与するために製剤化されている、請求項5に記載の医薬組成物。
- ヌクレオチド類縁化学療法剤が、クラドリビン、クロファラビン、フルダラビン、メルカプトプリン、ペントスタチン、チオグアニン、カペシタビン、シタラビン、デシタビン、フルオロウラシル、フロクスウリジン、サパシタビン、及びゲムシタビンよりなる群から選ばれる、請求項1〜6の何れか一項に記載の医薬組成物。
- ヌクレオチド類縁化学療法剤がゲムシタビンである、請求項7に記載の医薬組成物。
- 医薬組成物が、ゲムシタビンを500mg/m2/week〜1500mg/m2/weekの用量で投与するために製剤化されている、請求項8に記載の医薬組成物。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2008/005104 WO2009128805A1 (en) | 2008-04-17 | 2008-04-17 | On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011518153A JP2011518153A (ja) | 2011-06-23 |
JP2011518153A5 true JP2011518153A5 (ja) | 2011-08-04 |
JP5479453B2 JP5479453B2 (ja) | 2014-04-23 |
Family
ID=41199352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011504974A Expired - Fee Related JP5479453B2 (ja) | 2008-04-17 | 2008-04-17 | ON01910.Naは薬剤耐性腫瘍において化学療法剤活性を増強する |
Country Status (10)
Country | Link |
---|---|
US (2) | US8962614B2 (ja) |
EP (1) | EP2271339A4 (ja) |
JP (1) | JP5479453B2 (ja) |
KR (1) | KR101707669B1 (ja) |
CN (1) | CN102056607B (ja) |
AU (1) | AU2008354754B2 (ja) |
CA (1) | CA2721722C (ja) |
NZ (1) | NZ588749A (ja) |
RU (1) | RU2476239C2 (ja) |
WO (1) | WO2009128805A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009128805A1 (en) * | 2008-04-17 | 2009-10-22 | The Johns Hopkins University | On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors |
US10576050B2 (en) * | 2012-12-07 | 2020-03-03 | Onconova Therapeutics, Inc. | Methods and compositions for treatment of cancer |
US9566280B2 (en) | 2014-01-28 | 2017-02-14 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
ES2836772T3 (es) | 2014-04-30 | 2021-06-28 | Fujifilm Corp | Composición liposomal y método para producirla |
CN113633656A (zh) | 2015-02-25 | 2021-11-12 | 柏业公司 | 包含微小核糖核酸作为活性成分的用于治疗癌症的药物组合物 |
US10669302B2 (en) * | 2015-08-28 | 2020-06-02 | Zhejianf Hisun Pharmaceutical Co., Ltd. | Crystal form of fludarabine phosphate, preparation method therefor, and application thereof |
CN109232403A (zh) * | 2017-07-10 | 2019-01-18 | 亚宝药业集团股份有限公司 | 作为蛋白激酶抑制剂的酰胺类前药衍生物 |
EP4048284A4 (en) * | 2019-10-21 | 2023-11-01 | Acura Nanomedicine Corporation | METHOD FOR TREATING CANCER |
WO2023158514A1 (en) | 2022-02-18 | 2023-08-24 | Massachusetts Institute Of Technology | Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2321454A (en) * | 1997-01-24 | 1998-07-29 | Norsk Hydro As | Gemcitabine esters and amides |
US7037906B1 (en) | 2000-12-22 | 2006-05-02 | Oxigene, Inc. | Methods for modulating tumor growth and metastasis |
WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
US20070197538A1 (en) | 2004-10-07 | 2007-08-23 | Mark Nesbit | Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors |
TW200621240A (en) * | 2004-11-05 | 2006-07-01 | Salmedix Inc | Cancer treatments |
CA2593523C (en) | 2005-01-05 | 2014-04-08 | Temple University - Of The Commonwealth System Of Higher Education | Treatment of drug-resistant proliferative disorders |
US7504513B2 (en) * | 2006-02-27 | 2009-03-17 | Hoffman-La Roche Inc. | Thiazolyl-benzimidazoles |
JP5278968B2 (ja) | 2006-08-30 | 2013-09-04 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法 |
JP5528806B2 (ja) * | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
US20080279874A1 (en) * | 2007-05-07 | 2008-11-13 | Wyeth | Compositions and methods for modulation of plk1 kinase activity |
WO2009128805A1 (en) * | 2008-04-17 | 2009-10-22 | The Johns Hopkins University | On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors |
-
2008
- 2008-04-17 WO PCT/US2008/005104 patent/WO2009128805A1/en active Application Filing
- 2008-04-17 CN CN200880129775.1A patent/CN102056607B/zh not_active Expired - Fee Related
- 2008-04-17 CA CA2721722A patent/CA2721722C/en not_active Expired - Fee Related
- 2008-04-17 KR KR1020107025808A patent/KR101707669B1/ko active IP Right Grant
- 2008-04-17 NZ NZ588749A patent/NZ588749A/en not_active IP Right Cessation
- 2008-04-17 US US12/988,471 patent/US8962614B2/en not_active Expired - Fee Related
- 2008-04-17 JP JP2011504974A patent/JP5479453B2/ja not_active Expired - Fee Related
- 2008-04-17 EP EP08743127A patent/EP2271339A4/en not_active Withdrawn
- 2008-04-17 RU RU2010145048/15A patent/RU2476239C2/ru not_active IP Right Cessation
- 2008-04-17 AU AU2008354754A patent/AU2008354754B2/en not_active Ceased
-
2015
- 2015-02-17 US US14/624,057 patent/US9545418B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011518153A5 (ja) | ||
Hu et al. | DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application | |
JP2014177455A5 (ja) | ||
IL264288A (en) | Methods and preparations for regulating expression of apolipoprotein(a) | |
JP2018126141A5 (ja) | ||
Peters | Novel developments in the use of antimetabolites | |
NZ602833A (en) | Oral formulations of cytidine analogs and methods of use thereof | |
PH12015502273A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
HRP20120419T1 (hr) | Fluoro deoksitetrahidrouridini kao inhibitori citidin deaminaze | |
JP2016501513A5 (ja) | ||
PH12014502094A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
NO20066081L (no) | Kinazolinderivater som erbB-reseptortyrosinkinaser | |
GEP201706793B (en) | Substituted nucleosides, nucleotides and analogs thereof | |
JP2011501962A5 (ja) | ||
JP2014521310A5 (ja) | ||
RU2010145048A (ru) | On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях | |
Valenzuela et al. | Antimetabolite treatment for pancreatic cancer | |
JP2019536767A5 (ja) | ||
Yang et al. | A novel cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to gemcitabine | |
JP2009505991A5 (ja) | ||
Hosokawa et al. | Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine | |
JP2017516827A5 (ja) | ||
Zhang et al. | Quercetin downregulates the expression of IL15 in cancer cells through DNA methylation. | |
TWI615145B (zh) | 含伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
JP2007513202A5 (ja) |